These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 19047127

  • 1. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML.
    Clin Cancer Res; 2008 Dec 01; 14(23):7947-55. PubMed ID: 19047127
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
    Beutel G, Glen H, Schöffski P, Chick J, Gill S, Cassidy J, Twelves C.
    Clin Cancer Res; 2005 Aug 01; 11(15):5487-95. PubMed ID: 16061865
    [Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
    Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC, EORTC New Drug Development Group.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):579-85. PubMed ID: 17520255
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW.
    J Pharmacol Exp Ther; 2004 Jun 01; 309(3):894-902. PubMed ID: 14982966
    [Abstract] [Full Text] [Related]

  • 5. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
    Vokes EE, Goh BC, Bertucci D, Vogelzang NJ, Mani S, Ratain MJ.
    Cancer; 1999 Aug 01; 86(3):528-32. PubMed ID: 10430263
    [Abstract] [Full Text] [Related]

  • 6. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK, Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):703-10. PubMed ID: 16528532
    [Abstract] [Full Text] [Related]

  • 7. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 2001 Jul 01; 7(7):1901-11. PubMed ID: 11448903
    [Abstract] [Full Text] [Related]

  • 8. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N, Aiba K, Fukuoka M, Akazawa S, Sakata Y, Furuse K, Kanamaru R, Kudoh S, Konishi T, Kurihara M, Niitani H, Furue H, Tsukagoshi S, Taguchi T, Yoshida S, Ota K, Kotake T, Wakui A.
    Gan To Kagaku Ryoho; 1998 Nov 01; 25(13):2075-84. PubMed ID: 9838910
    [Abstract] [Full Text] [Related]

  • 9. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.
    Clin Cancer Res; 1999 Sep 01; 5(9):2381-91. PubMed ID: 10499608
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A.
    Cancer Chemother Pharmacol; 2009 Dec 01; 65(1):167-75. PubMed ID: 19449006
    [Abstract] [Full Text] [Related]

  • 11. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
    Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK.
    Clin Cancer Res; 2008 Jul 15; 14(14):4484-90. PubMed ID: 18628463
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan 15; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 13. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
    Ciuleanu T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, Herrmann T, Roth A, Chick J, Brock K, Albert D, Philip PA.
    Invest New Drugs; 2007 Aug 15; 25(4):385-90. PubMed ID: 17364234
    [Abstract] [Full Text] [Related]

  • 14. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
    Siegel-Lakhai WS, Beijnen JH, Vervenne WL, Boot H, Keessen M, Versola M, Koch KM, Smith DA, Pandite L, Richel DJ, Schellens JH.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4495-502. PubMed ID: 17671135
    [Abstract] [Full Text] [Related]

  • 15. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.
    Clin Cancer Res; 2008 May 15; 14(10):3105-12. PubMed ID: 18483378
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R.
    Cancer Chemother Pharmacol; 2006 Jun 15; 57(6):727-35. PubMed ID: 16261364
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
    Johansen M, Zukowski T, Hoff PM, Newman RA, Ni D, Hutto T, Abbruzzeese J, Berghorn E, Hausheer F, Madden T.
    Cancer Chemother Pharmacol; 2004 May 15; 53(5):370-6. PubMed ID: 15060739
    [Abstract] [Full Text] [Related]

  • 20. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
    Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J.
    Br J Cancer; 2006 Aug 21; 95(4):450-6. PubMed ID: 16880795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.